Proactol XS – Weight Loss Pill Backed up by Over 40 Clinical Studies

Proactol XS is a product that claims to help you lose weight safely and within a short period of time. It is a clinically proven fat binder, that is, it reduces the fat intake so as to help in weight loss. Proactol is basically a natural source of fibers, which work to bind fats.

This is what Proactol is in a nutshell. But let us go into some more detail as to whether it is a weight loss product worth trying out.

Pros and Cons of Proactol XS

One of the best things about Proactol is the fact that it is backed up by over 40 clinical studies. This seems to agree that it is a safe and effective weight loss product. It is also basically a natural product since it is mainly composed of safe ingredients.

The manufacturing company offers peace of mind to clients thanks to a money back guarantee. The company itself seems to be reputable as it is one of the leading UK based manufacturers of dietary supplements.

There seem to be several positive reviews about the effectiveness of Proactol XS. It seems that its fat binding is very effective for weight loss, and when compared to competing for fat binding products it is said to be 33% more effective.

The drawbacks of this product mainly revolve around the fact that despite the fact that it has been clinically tested, there are still some users who claimed that they suffered from some side effects.

Some complained of stomach aches and nausea, and others mentioned vomiting and diarrhea. However for the majority of users, no side effects were reported, and it is safe to state that since Proactol XS is mainly made from natural components, the prevalence of side effects is quite minimal.

How does Proactol XS work?

Proactol XS helps you to:

Lose weight quickly

Bind fats

Reduce body mass

Control your cravings

The main function of Proactol XS, like any other fat binder, is to help the body reduce its absorption of fats. As a result, this reduces the calorie intake, and the weight can be maintained at an acceptable level.

Proactol XS contains Chitosan, which is very effective in its fat binding capacity. In time, and according to reviews and studies, in the case of Proactol XS, it is a short time, the body fat will start to diminish and so one can achieve the figure he or she always wanted.

Proactol XS Ingredients and Daily Intake

Proactol XS comes in the form of capsules. One should take two capsules up to three times a day.

Is Proactol XS really effective?

All in all, there are many positive reviews about this product. Moreover, since it is made from natural components, produced by a company of good standing, backed by clinical studies and a money back guarantee, it can be concluded that it may be a product worth trying out.

For the chemically minded read more about Proactol XS Studies:

KiOmedine-CsU®, The World’s First GMP Ultra-pure Chitosan of Non-animal Origin for Medical and Pharmaceutical Applications

In this article, we highlight the features and advantages of KiOmedine-CsU®, an ultra-pure biopolymer from the mushroom origin, and show how they benefit to medical and pharmaceutical scientists looking for innovative solutions in the medical and pharmaceutical fields.

ULTRA-PURE CHITOSAN FOR BIOMEDICAL APPLICATIONS

Chitosan is a bioresorbable cationic biopolymer made of D-glucosamine and N-acetyl-D-glucosamine that is increasingly used in pharmaceutical formulations, wound and hemostats, regenerative medicine and medical devices for biosurgery (TABLE 1).

Many studies have highlighted the unique features brought by chitosan in pharmaceutical formulations, especially in drug delivery systems like tablets, micro- and nanoparticles and hydrogels for mucosal delivery and vaccine delivery1-5. Chitosan is also well suited for the formulation of biopharmaceutical candidates like peptides, proteins, RNA, DNA6, 7. It brings unique functionalities like mucoadhesiveness, enhancement of bioavailability, enhanced crossing of biological barriers, bioresorbability, interactions with anionic molecules, easy and robust processing into various forms. Recently, Kean and Thanou have reviewed the large body of work available on in vivo degradation and toxicity of chitosan8. The authors concluded that chitosan could be considered as non-toxic and biocompatible.

Today, ultra-pure chitosan benefits from an extensive body of research and development in various fields, a large background in formulating and processing, a good safety profile, a large number of commercial biomedical products on the market (particularly for trauma hemostasis and wound care), an increasing amount of clinical studies underway using various therapeutics strategies and routes of administration.

The accepted definition of “ultra-pure chitosan” is a chitosan with low bioburden, endotoxin-free, manufactured in accordance with cGMP and suitable for various routes of administrations including the parenteral one, as well as implantable medical devices. It is defined by monographies in the European and US Pharmacopeias.

The traceability, the reliability and the reproducibility of the source of the biopolymer are of great importance. Up to recently, the most frequent commercial source of ultra-pure chitosan was the exoskeleton of shellfish (shrimps, crabs) and squid. For many years now, there has been extensive research to develop manufacturing of ultra-pure chitosan from non-animal sources. Microalgae and mushroom sources have recently become commercially available, both proving outstanding quality and consistency, thus overcoming some of the drawbacks of shellfish-derived ultra-pure chitosan9-11. Cultivated edible mushrooms like Agaricus bisporus contain substantial amounts of chitin as the main component of their cell walls. They are widely available from growers worldwide, in a very constant manner, which makes them a source of choice for the production of high-quality chitosan.

MANUFACTURING GMP ULTRA-PURE CHITOSAN OF MUSHROOM ORIGIN

The company KitoZyme has established a patented and fully validated GMP process for the manufacturing of ultra-pure chitosan from white edible mushrooms (Agaricus bisporus)11. It conforms to the requirements for use in all pharmaceuticals applications including parenteral, and in all medical devices applications including implants. KiOmedine-CsU® is manufactured following the ICH-Q7, Eudralex, and CFR21 guidelines, in KitoZyme’s ISO7/ISO8 production facility in Liège, Belgium.

A key aspect of the KiOmedine® technology is the control of the complete production process from the selection of the raw materials to the final packaging. The selected mushrooms are grown in batches by a large European producer in controlled chambers, enabling a traceable and reproducible source of supply. Controlled growing conditions allow tight regulation of starting a culture, growth substrate, light, temperature, and humidity. All this ensures a high consistency in the chitin and chitosan output.

Another key aspect is the high purity and the tight control of the molecular characteristics of chitosan, achieved thanks to a step-by-step process with strict in-process controls. The performances of chitosan are indeed ruled by its molecular characteristics (molecular weight and proportion of remaining N-acetyl-glucosamine groups versus the glucosamine groups), and the mushroom technology were proven to achieve a high control of these parameters.

KiOmedine-CsU®is available in a new range of 4 different molecular weights (TABLE 2), available from KitoZyme and in smaller quantities the

Kitozyme’s technology permits a tight management of the molecular characteristics of chitosan, enabling for the first time to supply an ultra-pure GMP chitosan now in the range of 30,000 to 200,000 with narrow polydispersity and consistency.

This enables the medical and pharmaceutical scientists to screen variable molecular characteristics for optimum and consistent performances, a requirement becoming increasingly important for excipients, and gives opportunities for quality-by-design developments, customized specifications and greater differentiation of the final formulations.

The microbiological quality of KiOmedine-CsU® is also excellent. A 1-year stability study shows that endotoxin, yeast and molds, and viable aerobic count levels remain very low with levels below 10EU/g, 10cfu/g and 100cfu/g, respectively.

The safety and efficacy of KiOmedine-CsU® was proven in different formulations and therapeutic strategies, such as the preparation of nanoparticles12-15, tubes and fibres16, neocartilage scaffolds17, hydrogel microbeads18 and surgical devices19. In a recent publication15, low molecular weight KiOmedine-CsU® (Mw ca. 40,000) was proved to be the most suitable to prepare siRNA/chitosan polyplexes that achieved fast cellular uptake kinetics and appropriate size and shape.

CONCLUSION

KiOmedine-CsU®, the world’s first ultra-pure GMP chitosan of non-animal origin, sets a new benchmark in strategic medical and pharmaceutical areas. The availability of this biopolymer with unique features is triggering new developments of chitosan-based pharmaceutical and medical device applications beyond topical and hemostatic use. It makes it easier to bring a product to the market thanks to a 100% animal-free process and outstanding consistent characteristics. With the broader features of this new ultra-pure chitosan in hand, innovative drug delivery, cell therapy, pharmaceutical and medical device companies should be keener to take a closer look at the performances of chitosan-based systems. KiOmedine® undeniably injects the right solution for safety innovations and better developments in the medical and pharmaceutical business.